...
首页> 外文期刊>Obstetrics and Gynecology >Combination estrogen-progestin contraceptives and body weight: systematic review of randomized controlled trials.
【24h】

Combination estrogen-progestin contraceptives and body weight: systematic review of randomized controlled trials.

机译:雌激素-孕激素组合避孕药和体重:随机对照试验的系统评价。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

OBJECTIVE: Many women and clinicians believe that combination estrogen-progestin contraceptive use can lead to weight gain. This concern can deter women from starting hormonal contraception or lead to premature quitting. This review evaluated the association between combination contraceptive use and change in body weight. DATA SOURCES: The computerized databases CENTRAL, MEDLINE, EMBASE, Popline, and LILACS (from their inception to 2002) were used to conduct this review. Known investigators and manufacturers were contacted for information about other trials not discovered in the database search. METHODS OF STUDY SELECTION: All English-language, randomized controlled trials measuring weight change that were at least 3 treatment cycles in duration and that compared a combination contraceptive to a placebo or to a combination contraceptive that differed in drug, dosage, regimen, or study length were eligible for inclusion. Of the 570 reports of randomized controlled trials of eligible interventions that were identified, 42 trials were included in the systematic review. TABULATION, INTEGRATION, AND RESULTS: Two reviewers independently abstracted data from the eligible trials using a standard form. Depending on the data available, the weighted mean difference using a fixed effect model with 95% confidence intervals was calculated for the mean change in weight between baseline and posttreatment measurements or the Peto odds ratio with 95% confidence intervals was calculated by using the proportion of women who gained or lost more than a specified amount of weight. The 3 placebo-controlled, randomized trials did not find evidence supporting a causal association between combination oral contraceptives or a combination skin patch and weight gain. Most comparisons from the 40 trials that compared 2 or more combination contraceptives showed no substantial difference in weight. In addition, discontinuation of combination contraceptives because of weight gain did not differ between groups when this factor was studied.CONCLUSION: Available evidence is insufficient to determine the effect of combination contraceptives on weight, but no large effect is evident.
机译:目的:许多妇女和临床医生认为,雌,孕激素联合使用避孕药具可导致体重增加。这种担心会阻止妇女开始荷尔蒙避孕或导致过早戒烟。该评价评估了联合使用避孕药具与体重变化之间的关联。数据来源:使用计算机数据库CENTRAL,MEDLINE,EMBASE,Popline和LILACS(从成立到2002年)进行了此次审查。与已知的研究人员和制造商联系,以获得有关在数据库搜索中未发现的其他试验的信息。研究选择方法:所有体重变化持续时间至少3个治疗周期的英语随机对照试验,其比较了避孕药与安慰剂的组合或与避孕药,药物,剂量,方案或研究不同的组合长度符合纳入条件。在确定的570项合格干预措施的随机对照试验报告中,有42项试验被纳入系统评价。制表,整合和结果:两位审阅者使用标准表格独立地从符合条件的试验中提取了数据。根据可用数据,使用基线为95%置信区间的固定效应模型,计算基线和治疗后测量之间的体重平均变化的加权均值差;或者,使用95%置信区间的Peto比值比,计算为体重增加或减少的女性。 3项安慰剂对照的随机试验未发现证据支持口服避孕药或皮肤贴剂与体重增加之间存在因果关系。来自40个试验的大多数比较结果均比较了2种或更多组合避孕药具的重量,但无明显差异。此外,研究该因素后,因体重增加而终止联合避孕药的使用也无差异。结论:现有证据不足以确定联合避孕药对体重的影响,但效果不明显。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号